Abvc Biopharma Inc's Comment on Sales, Marketing and Customers
The Company has collaboration agreements with BHK and Rgene Corporation. Under the BHK Co-Development Agreement, effective for fifteen years from the first commercial sale in Asia excluding Japan, the Company received milestone payments and is entitled to royalties from BHK's net sales of ABV-1501, ABV-1504, and ABV-1505 products. As of December 31, 2022, the Company completed phase II clinical trials for ABV-1504 for major depressive disorder (MDD) but had not completed phase II trials for ABV-1505 for attention deficit hyperactivity disorder (ADHD). The Rgene Agreement covers co-development and commercialization of therapies for HER2/neu positive breast cancer, pancreatic cancer, and ovarian cancer. The Company received $3,000,000 in cash or stock from Rgene as compensation for past research efforts. Development costs are shared equally between the Company and Rgene, and future net licensing income or net sales profits are split 50/50. An amendment to the Rgene Agreement removed two therapies and added a new therapy targeting EGFR positive non-small cell lung cancer. All research projects under this agreement are managed and funded equally by both parties. Customers and markets referenced in filings include BHK, BioLite Inc., BioLite Taiwan, BriVision, Rgene Corporation, and YuanGene Corporation.
The clinical-stage biopharmaceutical company, ABVC BioPharma Inc. (NASDAQ: ABVC), publicized a new global definitive licensing deal with OncoX, a dietary supplements specialist in oncology. The deal focuses on propelling treatment options for Non-Small Cell Lung Cancer (NSCLC). ABVC and its associate, Rgene Corporation, will tackle clinical testing, registration, manufacturing, supply, and distribution of a single-herb botanical drug extract from Maitake Mushroom (Grifola Frondosa), specifically for treating NSCLC. An income of $12.5 million, which can be distributed as either cash or shares in OncoX securities, is stipulated in the agreement. This sum is to be remitted within 30 days of signing the deal. An...
ABVC BioPharma, a clinical-stage biopharmaceutical company specializing in ophthalmology, CNS, and oncology/hematology, has announced a significant global licensing deal for its medical device, Vitargus. The company, along with its subsidiary BioFirst Corporation, entered into an agreement with ForSeeCon Eye Corporation (FEYE) to license the Ophthalmology pipeline, including the highly valued Vitargus device. The licensing income from this deal amounts to $33.5 million, with potential royalties reaching up to $60 million.Vitargus, valued at $187 million by a third-party valuer, is a medical device developed by ABVC BioPharma that aims to provide therapeutic solutions for various eye-related conditions. This ...
Abvc Biopharma Inc’s Comment on Sales, Marketing and Customers
The Company has collaboration agreements with BHK and Rgene Corporation. Under the BHK Co-Development Agreement, effective for fifteen years from the first commercial sale in Asia excluding Japan, the Company received milestone payments and is entitled to royalties from BHK's net sales of ABV-1501, ABV-1504, and ABV-1505 products. As of December 31, 2022, the Company completed phase II clinical trials for ABV-1504 for major depressive disorder (MDD) but had not completed phase II trials for ABV-1505 for attention deficit hyperactivity disorder (ADHD). The Rgene Agreement covers co-development and commercialization of therapies for HER2/neu positive breast cancer, pancreatic cancer, and ovarian cancer. The Company received $3,000,000 in cash or stock from Rgene as compensation for past research efforts. Development costs are shared equally between the Company and Rgene, and future net licensing income or net sales profits are split 50/50. An amendment to the Rgene Agreement removed two therapies and added a new therapy targeting EGFR positive non-small cell lung cancer. All research projects under this agreement are managed and funded equally by both parties. Customers and markets referenced in filings include BHK, BioLite Inc., BioLite Taiwan, BriVision, Rgene Corporation, and YuanGene Corporation.
Sources:
Abvc Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Abvc Biopharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Abvc Biopharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
